ERBB2 and gastric carcinoma: EGFR and HER2 are amplified and overexpressed in many human epithelial malignancies, including NSCLC, breast cancer, ovarian cancer, and other forms of cancer; they have both been identified as potential therapeutic targets in several solid tumors, although few reports have focused on gastric carcinoma [3-5].